Gerald M Walsh Selected Research

5-imino-13-deoxydoxorubicin

1/2019	A phase II clinical study of 13-deoxy, 5-iminodoxorubicin (GPX-150) with metastatic and unresectable soft tissue sarcoma.
6/2015	Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gerald M Walsh Research Topics

Disease

5	Cardiotoxicity 01/2019 - 03/2002
1	Sarcoma (Soft Tissue Sarcoma) 01/2019
1	Neutropenia 06/2015
1	Neoplasms (Cancer) 06/2015
1	Inflammation (Inflammations) 06/2007
1	Contact Dermatitis (Eczema, Contact) 06/2007

Drug/Important Bio-Agent (IBA)

4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019 - 03/2002
3	AnthracyclinesIBA 12/2016 - 03/2002
2	5-imino-13-deoxydoxorubicinIBA 01/2019 - 06/2015
2	5-iminodoxorubicinIBA 01/2019 - 12/2016
2	3,4-dihydroxybenzohydroxamic acidIBA 12/2016 - 06/2007
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019
1	DNA (Deoxyribonucleic Acid)IBA 12/2016
1	Kinetoplast DNA (kDNA)IBA 12/2016
1	quinone (benzoquinone)IBA 12/2016
1	adriamycinolIBA 03/2002
1	Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA 03/2002

Therapy/Procedure

1	Drug Tapering 06/2015